Key Points
- Insider sale: Tuyl Christopher Van sold 2,877 shares of Immunovant (IMVT) on March 18 at an average price of $24.97, generating about $71,839 and reducing his stake by 1.92% to 147,053 shares valued at roughly $3.67M.
- Market and outlook: IMVT opened at $22.98 (down ~2.8%) with a market cap of $4.68B and a 12‑month range of $12.72–$29.25; the company reported Q4 EPS of −$0.61 (beating estimates) while analysts remain mixed with an average "Hold" rating and an average price target of $32 (individual targets roughly $18–$50).
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Tuyl Christopher Van sold 2,877 shares of the business's stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $24.97, for a total value of $71,838.69. Following the completion of the sale, the insider directly owned 147,053 shares in the company, valued at approximately $3,671,913.41. The trade was a 1.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Immunovant Trading Down 2.8%
IMVT opened at $22.98 on Friday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -8.54 and a beta of 0.62. The stock's 50-day moving average price is $26.09 and its 200 day moving average price is $22.90. Immunovant, Inc. has a 12-month low of $12.72 and a 12-month high of $29.25.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings results on Friday, February 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.11. During the same quarter last year, the firm posted ($0.76) EPS. On average, research analysts forecast that Immunovant, Inc. will post -2.69 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on IMVT shares. Guggenheim raised their price objective on shares of Immunovant from $41.00 to $44.00 and gave the company a "buy" rating in a report on Monday, February 9th. The Goldman Sachs Group boosted their price objective on Immunovant from $18.00 to $28.00 and gave the company a "neutral" rating in a research note on Monday, December 15th. Wolfe Research raised shares of Immunovant from a "peer perform" rating to an "outperform" rating and set a $50.00 target price for the company in a report on Tuesday, January 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Immunovant in a research note on Friday, January 9th. Finally, Sanford C. Bernstein started coverage on shares of Immunovant in a research report on Friday. They issued a "market perform" rating and a $28.00 price objective for the company. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $32.00.
Get Our Latest Stock Analysis on IMVT
Hedge Funds Weigh In On Immunovant
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMVT. Invesco Ltd. raised its holdings in shares of Immunovant by 16.0% in the fourth quarter. Invesco Ltd. now owns 88,857 shares of the company's stock worth $2,259,000 after acquiring an additional 12,255 shares during the last quarter. Empowered Funds LLC raised its stake in Immunovant by 4.5% during the fourth quarter. Empowered Funds LLC now owns 14,175 shares of the company's stock worth $360,000 after purchasing an additional 610 shares during the period. XTX Topco Ltd raised its position in shares of Immunovant by 91.2% in the 4th quarter. XTX Topco Ltd now owns 33,122 shares of the company's stock worth $842,000 after buying an additional 15,795 shares during the period. VARCOV Co. purchased a new position in shares of Immunovant in the 4th quarter worth about $404,000. Finally, Virtus Investment Advisers LLC raised its holdings in Immunovant by 41.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,069 shares of the company's stock valued at $256,000 after buying an additional 2,931 shares during the period. Institutional investors and hedge funds own 47.08% of the company's stock.
Immunovant Company Profile
(
Get Free Report)
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
